Amer a. beg
Deparment of Immunology
Moffitt Cancer Center
United States of America
Dr. Amer A. Beg is affiliated to Deparment of Immunology, Moffitt Cancer Center. Dr. Amer A. Beg is currently providing services as Researcher. Dr. Amer A. Beg has authored and co-authored multiple peer-reviewed scientific papers and presented works at many national and International conferences. Dr. Amer A. Beg contributions have acclaimed recognition from honourable subject experts around the world. Dr. Amer A. Beg is actively associated with different societies and academies. Dr. Amer A. Beg academic career is decorated with several reputed awards and funding. Dr. Amer A. Beg research interests include NF-kappa B subunits regulate unique aspects of DC function can open up new avenues to modulate DC function in cancer.
NF-kappa B subunits regulate unique aspects of DC function can open up new avenues to modulate DC function in cancer
Zheng H, Zhao W, Yan C, Watson CC, Massengill M, Xie M, Massengill C, Noyes DR, Martinez GV, Afzal R, Chen Z. HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma. Clinical Cancer Research. 2016 Aug 15;22(16):4119-32.
Chen L, Engel BE, Welsh EA, Yoder SJ, Brantley SG, Chen DT, Beg AA, Cao C, Kaye FJ, Haura EB, Schabath MB. A sensitive NanoString-based assay to score STK11 (LKB1) pathway disruption in lung adenocarcinoma. Journal of Thoracic Oncology. 2016 Jun 30;11(6):838-49.
Schabath MB, Welsh EA, Fulp WJ, Chen L, Teer JK, Thompson ZJ, Engel BE, Xie M, Berglund AE, Creelan BC, Antonia SJ. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene. 2016 Jun 16;35(24):3209.